GO:0090212 negative regulation of establishment of blood-brain barrier: Barrier Disruption Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090212 describes any process that decreases the rate, frequency or extent of establishment of the blood-brain barrier (BBB), a selectively permeable barrier between capillaries and the brain.
• Loss of BBB integrity is driven by tight junction disassembly, endothelial oxidative stress, and inflammatory signaling, as shown for bacterial meningitis and THC exposure.
• Key molecular players include CX43, PARP1, ZO-1, AIMP1, BDNF, CB1R, PKC-beta, and circNAV3-ST6GALNAC5-EGFR axis components.
• NAD+ rescue via the CX43-PARP1 axis reverses aging-induced BBB damage, directly linking metabolism to negative regulation of BBB establishment.
• miR-155/BDNF and let-7f-5p/AIMP1/ZO-1 axes are experimentally tractable regulators of BBB disruption in meningitis and neuromyelitis optica spectrum disorders.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of candidate genes in BBB establishment and disruption.
Description
The blood-brain barrier (BBB) is a selectively permeable structural and functional barrier that exists between the capillaries and the brain, and its establishment is a tightly regulated developmental and homeostatic process. GO:0090212, negative regulation of establishment of blood-brain barrier, captures any process that decreases the rate, frequency or extent of this barrier formation. Understanding this term is critical because excessive negative regulation manifests as barrier breakdown, which is a hallmark of neuroinflammatory, infectious, metabolic and metastatic disease.
negative regulation of establishment of blood-brain barrier At A Glance
| GO ID | GO:0090212 |
|---|---|
| GO term | negative regulation of establishment of blood-brain barrier |
| Ontology | biological_process |
| Synonym | negative regulation of establishment of BBB |
| Major function | Decreases the rate, frequency or extent of blood-brain barrier establishment |
| Definition source | QuickGO definition: any process that decreases the rate, frequency or extent of the establishment of the blood-brain barrier |
| Associated processes | Tight junction disassembly, oxidative stress, inflammatory signaling, endothelial metabolic stress |
| Representative regulators | CX43, PARP1, ZO-1, AIMP1, BDNF, CB1R, PKC-beta |
| Disease relevance | Bacterial meningitis, neuromyelitis optica spectrum disorders, brain metastasis, aging-related BBB damage |
What Is GO:0090212?
GO:0090212 (negative regulation of establishment of blood-brain barrier) is a biological_process term defined as any process that decreases the rate, frequency or extent of the establishment of the blood-brain barrier, a selectively permeable structural and functional barrier that exists between the capillaries and the brain. In practice, this term covers molecular and cellular events that weaken or delay BBB formation, including tight junction degradation, endothelial oxidative stress, and inflammatory signaling that destabilizes the neurovascular unit.
Why Is negative regulation of establishment of blood-brain barrier Important in Cell Biology?
GO:0090212 is important because negative regulation of BBB establishment is a convergent node for infectious, inflammatory, metabolic and metastatic brain injury, and its experimental manipulation can reveal causal drivers of barrier failure. Because BBB disruption permits pathogen entry, immune cell infiltration and drug or metabolite leakage, genes annotated to this term are high-value targets for neuroprotective and CNS drug-delivery research.
• Bacterial pathogens disrupt the BBB through multiple mechanisms, making GO:0090212 central to meningitis research.
• Aging-induced BBB damage is rescued by NAD+ via the CX43-PARP1 axis, linking metabolism to this GO term.
• Delta-9-tetrahydrocannabinol induces BBB disruption through CB1R activation and oxidative stress.
• miR-155/BDNF signaling modulates BBB integrity in bacterial meningitis models.
• let-7f-5p/AIMP1/ZO-1 axis mediates BBB dysfunction in neuromyelitis optica spectrum disorders.
• circNAV3-ST6GALNAC5-EGFR axis reduces brain metastasis by influencing BBB-related biology.
• PKC-beta distinctly regulates BBB-forming capacity of brain microvascular endothelial cells.
• Spironolactone has been reviewed for cognitive benefits in renal dysfunction, a condition linked to BBB compromise.
• Hyperoside impacts BBB integrity in bacterial meningitis via the miR-155/BDNF pathway.
• Isoliquiritigenin reduces brain metastasis through a circNAV3-ST6GALNAC5-EGFR axis.
What Happens During negative regulation of establishment of blood-brain barrier?
Tight junction destabilization
In simple terms: The glue that seals the barrier between blood vessels and brain is loosened.
Negative regulation of BBB establishment frequently begins with destabilization of tight junctions, including reduced ZO-1 integrity, which increases paracellular permeability. In neuromyelitis optica spectrum disorders, the let-7f-5p/AIMP1/ZO-1 axis mediates BBB dysfunction, directly linking microRNA regulation to tight junction loss. Bacterial pathogens also disrupt tight junctions as part of BBB breakdown.
Oxidative stress and endothelial injury
In simple terms: Chemical stress damages the cells that form the barrier.
Oxidative stress is a major driver of negative regulation of BBB establishment. Delta-9-tetrahydrocannabinol induces BBB disruption involving activation of CB1R and oxidative stress. NAD+ rescues aging-induced BBB damage via the CX43-PARP1 axis, indicating that metabolic and oxidative stress pathways converge on barrier maintenance.
Inflammatory and infectious signaling
In simple terms: Infection and inflammation send signals that open the barrier.
Different types of bacteria disrupt the BBB through distinct mechanisms, and bacterial-host interactions facilitate pathogen invasion of the brain. In bacterial meningitis, Hyperoside impacts the BBB through the microRNA-155/brain-derived neurotrophic factor pathway, showing that inflammatory microRNA signaling can modulate barrier integrity.
Metastasis-associated barrier modulation
In simple terms: Cancer cells can alter the barrier to help spread to the brain.
Isoliquiritigenin reduces brain metastasis by acting on the circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer, a pathway that intersects with BBB-related biology. This illustrates how negative regulation of BBB establishment can be co-opted in metastatic disease.
Endothelial cell capacity and PKC-beta signaling
In simple terms: The intrinsic ability of barrier-forming cells is controlled by specific kinases.
Protein kinase C-beta distinctly regulates the BBB-forming capacity of brain microvascular endothelial cells and outgrowth endothelial cells, highlighting cell-type-specific control of barrier establishment. This supports the idea that negative regulation can act by reducing the intrinsic barrier-forming capacity of endothelial cells.
Key Genes Involved in GO:0090212 negative regulation of establishment of blood-brain barrier
The following genes and proteins have been experimentally linked to negative regulation of blood-brain barrier establishment in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CX43 | Gap junction protein involved in NAD+ rescue of aging-induced BBB damage | Target for metabolic rescue of BBB integrity |
| PARP1 | DNA repair enzyme in CX43-PARP1 axis | Modulates aging-related BBB damage |
| ZO-1 | Tight junction protein whose loss increases permeability | Readout of BBB integrity in NMOSD models |
| AIMP1 | Target of let-7f-5p in BBB dysfunction | Mediates BBB dysfunction in NMOSD |
| BDNF | Neurotrophic factor in miR-155/BDNF pathway | Modulates BBB in bacterial meningitis |
| CB1R | Cannabinoid receptor activated by THC | Mediates THC-induced BBB disruption |
| PKC-beta | Kinase regulating BBB-forming capacity | Cell-type-specific regulator of barrier formation |
| circNAV3 | Circular RNA in circNAV3-ST6GALNAC5-EGFR axis | Linked to brain metastasis and BBB biology |
| ST6GALNAC5 | Sialyltransferase in circNAV3-ST6GALNAC5-EGFR axis | Modulates brain metastasis |
| EGFR | Receptor tyrosine kinase in circNAV3-ST6GALNAC5-EGFR axis | Target for reducing brain metastasis |
| miR-155 | MicroRNA regulating BDNF pathway | Modulates BBB in meningitis |
| let-7f-5p | MicroRNA targeting AIMP1 | Mediates BBB dysfunction in NMOSD |
| NAD+ | Metabolic cofactor rescuing BBB damage | Therapeutic metabolite for BBB integrity |
| Hyperoside | Natural compound impacting BBB in meningitis | Experimental modulator of BBB integrity |
| Isoliquiritigenin | Natural compound reducing brain metastasis | Experimental modulator of BBB-related metastasis |
| Spironolactone | Drug reviewed for cognitive benefits in renal dysfunction | Potential modulator of BBB-related cognitive outcomes |
| Delta-9-tetrahydrocannabinol | Cannabinoid inducing BBB disruption | Experimental disruptor of BBB |
How Is negative regulation of establishment of blood-brain barrier Regulated?
Negative regulation of BBB establishment is controlled by multiple intersecting pathways. The CX43-PARP1 axis mediates aging-induced BBB damage and is rescued by NAD+, indicating metabolic regulation. MicroRNA networks, including miR-155/BDNF and let-7f-5p/AIMP1/ZO-1, post-transcriptionally regulate barrier integrity. Oxidative stress and CB1R activation by delta-9-tetrahydrocannabinol provide pharmacological regulation. Protein kinase C-beta signaling regulates the intrinsic BBB-forming capacity of endothelial cells. Bacterial-host interactions provide an infectious layer of regulation.
negative regulation of establishment of blood-brain barrier and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CX43 | Aging-induced BBB damage | Knockout or overexpression in brain endothelial cells |
| PARP1 | Aging-related BBB damage | Point mutation or knockout in BBB models |
| ZO-1 | Neuromyelitis optica spectrum disorders | Knockdown or knockout in endothelial monolayers |
| AIMP1 | Neuromyelitis optica spectrum disorders | Knockout or rescue in BBB models |
| EGFR | Brain metastasis | Knockout or overexpression in metastatic models |
Bacterial meningitis
Bacterial pathogens disrupt the BBB through multiple mechanisms, and bacterial-host interactions facilitate pathogen invasion of the brain. Hyperoside impacts the BBB in rats with bacterial meningitis through the microRNA-155/brain-derived neurotrophic factor pathway, linking this GO term to infectious disease.
Neuromyelitis optica spectrum disorders
The let-7f-5p/AIMP1/ZO-1 axis mediates BBB dysfunction in neuromyelitis optica spectrum disorders, directly connecting negative regulation of BBB establishment to autoimmune neuroinflammatory disease.
Brain metastasis
Isoliquiritigenin reduces brain metastasis by acting on the circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer, implicating BBB-related biology in metastatic spread.
Aging and metabolic dysfunction
NAD+ rescues aging-induced BBB damage via the CX43-PARP1 axis, and spironolactone has been reviewed for cognitive benefits in renal dysfunction, linking this GO term to aging and metabolic disease.
From negative regulation of establishment of blood-brain barrier-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CX43 loss exacerbate aging-induced BBB damage? | CX43 knockout in brain endothelial cells |
| Does PARP1 inhibition rescue BBB integrity? | PARP1 point-mutation or knockout |
| Does ZO-1 loss increase permeability? | ZO-1 knockout or knockdown |
| Does AIMP1 mediate let-7f-5p effects? | AIMP1 knockout with let-7f-5p mimic |
| Does EGFR modulation alter brain metastasis? | EGFR overexpression or knockout |
| Does PKC-beta regulate barrier-forming capacity? | PKC-beta knockout in endothelial cells |
How to Study the negative regulation of establishment of blood-brain barrier Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript changes | Identify BBB regulators in disease models |
| microRNA profiling | MicroRNA expression changes | Discover miR-155 and let-7f-5p axes |
| Western blot | Protein levels of ZO-1, AIMP1, PKC-beta | Quantify barrier protein changes |
| Immunofluorescence | Tight junction localization | Assess BBB integrity |
| TEER assay | Barrier tightness | Functional BBB establishment readout |
| Tracer permeability | Leakage across BBB | In vivo and in vitro barrier function |
| CRISPR knockout | Loss-of-function effects | Causal testing of candidate genes |
| Overexpression | Gain-of-function effects | Test sufficiency of regulators |
Transcriptomic and microRNA profiling
RNA-seq and microRNA profiling can identify regulators such as miR-155 and let-7f-5p that modulate BBB establishment. These methods are used to discover differentially expressed genes in meningitis or NMOSD models.
Protein and tight junction analysis
Western blot and immunofluorescence for ZO-1 and other tight junction proteins quantify barrier integrity changes. Protein kinase C-beta levels can be assessed to study endothelial barrier-forming capacity.
Permeability assays
Transendothelial electrical resistance and tracer permeability assays measure functional BBB integrity in vitro and in vivo. These assays are standard for testing negative regulation of BBB establishment.
Pharmacological and genetic perturbation
Compounds such as Hyperoside, isoliquiritigenin, delta-9-tetrahydrocannabinol, and NAD+ are used to perturb BBB establishment pathways. Genetic perturbation via CRISPR complements these pharmacological approaches.
How CRISPR Can Be Used to Study GO:0090212 negative regulation of establishment of blood-brain barrier
Knockout
CRISPR knockout of genes such as CX43, PARP1, ZO-1, AIMP1, or PKC-beta enables loss-of-function testing of their role in negative regulation of BBB establishment. Knockout endothelial cells can be assayed for TEER and tight junction integrity.
Point Mutation
Point mutations can be introduced into genes like PARP1 or EGFR to dissect domain-specific functions in BBB regulation. This approach refines causal claims beyond simple knockout.
Knock-in
Knock-in of tagged versions of ZO-1 or AIMP1 allows live-cell imaging and interaction studies in BBB models. Tagged knock-in preserves endogenous regulation while enabling detection.
Overexpression
Overexpression of circNAV3, ST6GALNAC5, or EGFR can test sufficiency for modulating BBB-related metastasis. Overexpression of BDNF or PKC-beta can test their capacity to alter barrier establishment.
How EDITGENE Supports negative regulation of establishment of blood-brain barrier Research
Researchers studying negative regulation of establishment of blood-brain barrier-related genes often need to determine whether a candidate gene is causally involved in barrier disruption or protection. EDITGENE provides CRISPR-based knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening with bioinformatics to accelerate this causal testing.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of establishment of blood-brain barrier research.
Frequently Asked Questions About negative regulation of establishment of blood-brain barrier
What is GO:0090212?
GO:0090212 is the Gene Ontology term for negative regulation of establishment of blood-brain barrier, defined as any process that decreases the rate, frequency or extent of BBB establishment.
What genes are involved in negative regulation of establishment of blood-brain barrier?
Genes and proteins experimentally linked include CX43, PARP1, ZO-1, AIMP1, BDNF, CB1R, PKC-beta, circNAV3, ST6GALNAC5, and EGFR.
How is the blood-brain barrier disrupted in bacterial meningitis?
Bacterial pathogens disrupt the BBB through multiple mechanisms, and bacterial-host interactions facilitate pathogen invasion of the brain. Hyperoside impacts the BBB via the microRNA-155/BDNF pathway in meningitis models.
What is the role of NAD+ in BBB damage?
NAD+ rescues aging-induced BBB damage via the CX43-PARP1 axis, linking metabolic rescue to barrier integrity.
How does THC affect the blood-brain barrier?
Delta-9-tetrahydrocannabinol induces BBB disruption involving activation of CB1R and oxidative stress.
What is the let-7f-5p/AIMP1/ZO-1 axis?
This axis mediates BBB dysfunction in neuromyelitis optica spectrum disorders, linking microRNA regulation to tight junction loss.
Can CRISPR be used to study BBB establishment?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate genes in BBB establishment and disruption.
What diseases are linked to negative regulation of BBB establishment?
Linked diseases include bacterial meningitis, neuromyelitis optica spectrum disorders, brain metastasis, and aging-related BBB damage.
How does PKC-beta regulate the blood-brain barrier?
Protein kinase C-beta distinctly regulates the BBB-forming capacity of brain microvascular endothelial cells and outgrowth endothelial cells.
What methods study negative regulation of BBB establishment?
Common methods include RNA-seq, microRNA profiling, Western blot, immunofluorescence, TEER assays, tracer permeability, and CRISPR perturbation.
Conclusion
GO:0090212, negative regulation of establishment of blood-brain barrier, is a biologically and clinically important process term that captures how tight junction destabilization, oxidative stress, inflammatory signaling, and metabolic stress weaken the BBB. The cited literature identifies CX43, PARP1, ZO-1, AIMP1, BDNF, CB1R, PKC-beta, and the circNAV3-ST6GALNAC5-EGFR axis as key experimental entry points. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with CRISPR library screening and bioinformatics, provide a rigorous path to causal discovery in this field.
References
- 1. Zhan R et al.. 2023. NAD(+) rescues aging-induced blood-brain barrier damage via the CX43-PARP1 axis.. Neuron 111(22):3634-3649.e7 PMID: 37683629
- 2. Zhang T et al.. 2025. Impact of Hyperoside on the Blood-Brain Barrier in Rats with Bacterial Meningitis through the MicroRNA-155/Brain-Derived Neurotrophic Factor Pathway.. Neuroendocrinology 115(9):704-718 PMID: 40618728
- 3. Al-Obaidi MMJ et al.. 2018. Mechanisms of Blood Brain Barrier Disruption by Different Types of Bacteria, and Bacterial-Host Interactions Facilitate the Bacterial Pathogen Invading the Brain.. Cell Mol Neurobiol 38(7):1349-1368 PMID: 30117097
- 4. Zhang Q et al.. 2025. Δ(9)-tetrahydrocannabinol induces blood-brain barrier disruption: Involving the activation of CB1R and oxidative stress.. Neuropharmacology 270:110366 PMID: 39956317
- 5. Xie Y et al.. 2025. Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer.. Cancer Lett 624:217734 PMID: 40268132
- 6. Sharma A et al.. 2025. A second act for spironolactone: cognitive benefits in renal dysfunction - a critical review.. Metab Brain Dis 40(5):194 PMID: 40299184
- 7. Yuan C et al.. 2025. Let-7f-5p/AIMP1/ZO-1 axis mediates blood-brain barrier dysfunction in neuromyelitis optica spectrum disorders.. Clin Exp Immunol 219(1) PMID: 41316924
- 8. Kadir RRA et al.. 2022. Protein kinase C-β distinctly regulates blood-brain barrier-forming capacity of Brain Microvascular endothelial cells and outgrowth endothelial cells.. Metab Brain Dis 37(6):1815-1827 PMID: 35763197
